Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)

被引：153

作者：

Olanow, CW

Damier, P

Goetz, CG

Mueller, T

Nutt, J

Rascol, O

Serbanescu, A

Deckers, F

Russ, H

机构：

[1] CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA

[2] Hop Guillaume & Rene Laennec, INSERM, U437, Clin Neurol,Ctr Invest Clin, Nantes, France

[3] Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Sect Movement Disorders, Chicago, IL 60612 USA

[4] Ruhr Univ Bochum, St Josef Hosp, Neurol Klin, D-4630 Bochum, Germany

[5] Natl Parkinsons Fdn, Parkinsons Ctr Oregon, Dept Neurol, Portland, OR USA

[6] CHU Toulouse, Hop Purpan, Ctr Invest Clin, Toulouse, France

[7] ANA ASLAN Hosp, N Gh Lupu Hosp, Neurosci Dept, Bucharest, Romania

[8] Merck Pharmaceut KGaA, Darmstadt, Germany

来源：

CLINICAL NEUROPHARMACOLOGY | 2004年 / 27卷 / 02期

关键词：

sarizotan; Parkinson disease; SPLENDID;

D O I：

10.1097/00002826-200403000-00003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：58 / 62

页数：5

共 13 条

[1] Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models [J].

Bibbiani, F ;

Oh, JD ;

Chase, TN .

NEUROLOGY, 2001, 57 (10) :1829-1834

[2]

Fahn S, 1987, Recent Dev. Park. Dis, P153

[3] THE RELEVANCE OF THE LEWY BODY TO THE PATHOGENESIS OF IDIOPATHIC PARKINSONS-DISEASE [J].

GIBB, WRG ;

LEES, AJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1988, 51 (06) :745-752

[4]

Goetz CG, 1999, MOVEMENT DISORD, V14, P48

[5]

GOETZ CG, 1994, MOVEMENT DISORD, V9, P990

[6]

Guy W., 1976, ECDEU Assessment Manual for Psychopharmacology, V76, P217

[7] A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia [J].

Hauser, RA ;

Friedlander, J ;

Zesiewicz, TA ;

Adler, CH ;

Seeberger, LC ;

O'Brien, CF ;

Molho, ES ;

Factor, SA .

CLINICAL NEUROPHARMACOLOGY, 2000, 23 (02) :75-81

[8] CORE ASSESSMENT PROGRAM FOR INTRACEREBRAL TRANSPLANTATIONS (CAPIT) [J].

LANGSTON, JW ;

WIDNER, H ;

GOETZ, CG ;

BROOKS, D ;

FAHN, S ;

FREEMAN, T ;

WATTS, R .

MOVEMENT DISORDERS, 1992, 7 (01) :2-13

[9]

*MERCK PHARM KGAA, DAT FIL

[10]

Olanow CW, 2002, MOVEMENT DISORD, V17, pS326

← 1 2 →